Questions around this news
What did the HyBryte comparability study report?
The release says that after 12 weeks, 60% of patients treated with HyBryte achieved treatment success, compared with 20% of those treated with Valchlor. It also reports greater average improvement with HyBryte and no treatment-related adverse events in that group, while patients receiving Valchlor experienced multiple adverse reactions.
How is HyBryte intended to treat cutaneous T-cell lymphoma?
The release describes HyBryte as a photodynamic therapy based on synthetic hypericin sodium and says it uses visible light. It identifies cutaneous T-cell lymphoma as the condition being targeted, but does not provide further details about the treatment procedure or how the therapy acts on lymphoma cells.
What is cutaneous T-cell lymphoma?
Cutaneous T-cell lymphoma is a group of uncommon cancers in which certain T lymphocytes, a type of immune cell, become cancerous and affect the skin. It can cause skin changes such as patches or plaques. The condition’s course and symptoms vary, and diagnosis and treatment depend on the specific type and circumstances.
What is photodynamic therapy?
Photodynamic therapy uses a light-sensitive substance and a particular wavelength of light to produce a treatment effect in targeted tissue. Depending on the therapy, the substance may be applied to the skin or given another way before illumination. The release describes HyBryte as using visible light, but does not detail its administration procedure.
Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, highlighting favorable efficacy and safety outcomes. After 12 weeks, 60% of HyBryte-treated patients achieved treatment success compared to 20% for Valchlor, with greater average improvement and no treatment-related adverse events reported for HyBryte, while Valchlor patients experienced multiple adverse reactions, supporting HyBryte’s potential as a well-tolerated therapy for early-stage CTCL.
To view the full press release, visit https://ibn.fm/Eq1BX
About Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet’s Disease.
Our Public Health Solutions business segment includes development programs for RiVax(R), our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Soligenix
- Ticker
- NASDAQ: SNGX
Key figures
- Study assessment period
- 12 weeks
- HyBryte patients achieving treatment success
- 60%
- Valchlor patients achieving treatment success
- 20%
Products and programs
SEC filings
Earlier from Soligenix
- Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
- Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
- Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
- Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
- Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation
